Papi, Alberto <br/><br/>
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.  [electronic resource] 

 -  International journal of chronic obstructive pulmonary disease  2015 
 - 2431-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1178-2005 
<br/><br/><label>Standard No.: </label>10.2147/COPD.S93375  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adrenal Cortex Hormones--administration & dosage<br/>Adrenergic beta-2 Receptor Agonists--administration & dosage<br/>Androstadienes--administration & dosage<br/>Biomarkers--blood<br/>Bronchodilator Agents--administration & dosage<br/>Chemokines, CC--blood<br/>Clinical Protocols<br/>Disease Progression<br/>Double-Blind Method<br/>Drug Combinations<br/>Ethanolamines--administration & dosage<br/>Fluticasone<br/>Forced Expiratory Volume<br/>Formoterol Fumarate<br/>Humans<br/>Lung--drug effects<br/>Pulmonary Disease, Chronic Obstructive--blood<br/>Pulmonary Surfactant-Associated Protein D--blood<br/>Recovery of Function<br/>Research Design<br/>Spirometry<br/>Surveys and Questionnaires<br/>Time Factors<br/>Treatment Outcome<br/>Vital Capacity